Trial Profile

A Phase 1, Open Label Study of Drug-Drug Interaction, Pharmacokinetics, Safety, and Tolerability of Etrasimod in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrasimod (Primary) ; Fluconazole; Gemfibrozil; Rifampicin
Indications Alopecia areata; Atopic dermatitis; Crohn's disease; Eosinophilic oesophagitis; Inflammation; Ulcerative colitis
Focus Pharmacokinetics

Most Recent Events

28 Nov 2022 New trial record
26 Oct 2022 Results Results From a Phase 1 Drug-Drug Interaction Study in Healthy Volunteers Pharmacokinetics, Safety, and Tolerability of Etrasimod presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
11 Oct 2022 Results presented at the 30th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com